Abstract
We aimed to investigate 3,5,3′-triiodothyroacetic acid (TRIAC) effects on intact and atrophic skin induced by glucocorticoids (GCs) in rats and the effects induced by nanoencapsulation. The effects of TRIAC and nanoencapsulated TRIAC were evaluated on intact and atrophic skin in TRIAC experiment and nanoencapsulated TRIAC experiment, respectively. Both experiments had two phases: phase I, cutaneous atrophy was induced; phase II, TRIAC or nanoencapsulated TRIAC was administrated. Our results showed that topical use of TRIAC with or without nanoencapsulation was able to reverse cutaneous atrophy. Nanoencapsulated TRIAC showed less systemic changes than TRIAC; therefore, it is possibly a safer drug for topical administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Nanotechnology in Engineering and Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
